Summary
The aim of this study was to summarize the efficacy and tolerability of rotigotine in the treatment of primary restless legs syndrome (RLS). PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for English-language randomized controlled trials (RCTs) that assessed the effectiveness of rotigotine for RLS. The pooled mean change from baseline in International RLS (IRLS) Study Group Rating Scalescore and relative risk (RR) of response based on the Clinical Global Impression-Improvement (CGI-I) scale score were applied to evaluate the outcomes. The pooled proportions of adverse events (AEs) were also estimated. Six RCTs were included. The meta-analysis showed a favorable effectiveness of rotigotine versus placebo on RLS [mean change on IRLS score: mean difference (MD)=−4.80; 95% confidence interval (CI): −5.90 to −3.70; P<0.00001 and RR of response on CGI-I was 2.19; 95% CI: 1.86 to 2.58, P<0.00001]. The most common AEs were application site reactions, nausea, headache and fatigue. In general, rotigotine was well-tolerated in patients with primary RLS. Based on the findings from the meta-analysis, rotigotine was more significantly efficacious in the treatment of RLS than placebo. Nevertheless, long-term studies and more evidence of comparisons of rotigotine with other dopamine agonists are needed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Trenkwalder C, Paulus W, Walters AS. The restless legs syndrome. Lancet Neurol, 2005,4(8):465–475
Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med, 2003,4(2):101–119
Zucconi M, Ferini-Strambi L. Epidemiology and clinical findings of restless legs syndrome. Sleep Med, 2004,5(3): 293–299
Ohayon MM, O’Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev, 2012,16(4): 283–295
Nomura T, Inoue Y, Kusumi M, et al. Prevalence of restless legs syndrome in a rural community in Japan. Mov Disord, 2008,23(16):2363–2369
García-Borreguero D, Kohnen R, Högl B, et al. Validation of the Augmentation Severity Rating Scale (ASRS): A multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med, 2007,8(5):455–463
Trenkwalder C, Hening WA, Montagna P, et al. Treatment of restless legs syndrome: An evidence-based review and implications for clinical practice. Mov Disord, 2008,23(16): 2267–2302
Stiasny-Kolster K1, Kohnen R, Schollmayer E, et al. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord, 2004,19(12):1432–1438
Oertel WH, Benes H, Garcia-Borreguero D, et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dosefinding trial in Europe. Sleep Med, 2007,9(3):228–239
Swartz MK. The PRISMA statement: a guideline for systematic reviews and meta-analyses. J Pediatr Health Care, 2011,25(1):1–2
Mulrow CD, Oxman AD. Cochrane Collaboration Handbook. Oxford, UK: Cochrane Collaboration, 1996
Whitehead A. Meta-Analysis of Controlled Clinical Trials. Chichester, UK, New York, NY: John Wiley & Sons, 2002
Trenkwalder C, Benes H, Poewe W, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: A randomised, doubleblind, placebo-controlled trial. Lancet Neurol, 2008,7(7):595–604
Oertel WH, Benes H, Garcia-Borreguero D, et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: A randomized, double-blind, placebocontrolled, six-week dose-finding trial in Europe. Sleep Med, 2008,9(3): 228–239
Oertel WH, Benes H, Garcia-Borreguero D, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: A randomized, placebo-controlled polysomnographic study. Sleep Med, 2010,11(9):848–856
Hening WA, Allen RP, Ondo WG, et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord, 2010,25(11):1675–1683
Inoue Y, Shimizu T, Hirata K, et al. Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study. Sleep Med, 2013,14(11):1085–1091
Reynolds NA, Wellington K, Easthope SE. Rotigotine in Parkinson’s disease. CNS Drugs, 2005,19(11):973–981
Garcia-Borreguero D, Allen RP, Kohnen R, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med, 2007,8(5):520–530
Collado-Seidel V, Kazenwadel J, Wetter TC, et al. A controlled study of additional SR-Ldopa in L-dopa responsive RLS with late night symptoms. Neurology, 1999,52(2):285–290
LeWitt PA, Nausieda PA, Chang FL, et al. Rotigotine transdermal system in a multicenter trial of patients with advanced Parkinson’s disease as adjunctive therapy to levodopa. Neurology, 2006,66(Suppl 2):A184
Rascol O, Poewe W, Giladi N, et al. Rotigotine transdermal patch as adjunctive therapy in comparison to pramipexole. Eur J Neurol, 2006,13(Suppl 2):S321
Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology, 2006,67(6):1034–1039
Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry, 2004,75(1):92–97
Zucconi M, Ferri R, Allen R, et al. International Restless Legs Syndrome Study Group (IRLSSG). The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG). Sleep Med, 2006,7(2):175–183
Hornyak M, Trenkwalder C, Kohnen R, et al. Efficacy and safety of dopamine agonists in restless legs syndrome. Sleep Med, 2012,13(3):228–236
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ding, J., Fan, W., Chen, Hh. et al. Rotigotine in the treatment of primary restless legs syndrome: A meta-analysis of randomized placebo-controlled trials. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 35, 169–175 (2015). https://doi.org/10.1007/s11596-015-1406-5
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-015-1406-5